JHPCY (Jiangsu Hengrui Pharmaceuticals Co) Cyclically Adjusted Revenue per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JHPCY Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
71 GF Score
Price $13.60
GF Value $15.12
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted Revenue per Share?

Jiangsu Hengrui Pharmaceuticals Co JHPCY 71 Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus rates JHPCY with a GF Score™ of 71/100 and a GF Value™ of $15.12 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Jiangsu Hengrui Pharmaceuticals Co's adjusted revenue per share for the three months ended in Mar. 2026 was $0.352. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Jiangsu Hengrui Pharmaceuticals Co's average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 16.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Jiangsu Hengrui Pharmaceuticals Co was 23.30% per year. The lowest was 9.70% per year. And the median was 19.80% per year.

As of today (2026-07-30), Jiangsu Hengrui Pharmaceuticals Co's current stock price is $13.60. Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.00. Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jiangsu Hengrui Pharmaceuticals Co was 47.68. The lowest was 11.51. And the median was 19.37.


Jiangsu Hengrui Pharmaceuticals Co  (OTCPK:JHPCY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jiangsu Hengrui Pharmaceuticals Co was 47.68. The lowest was 11.51. And the median was 19.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted Revenue per Share Related Terms


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted Revenue per Share Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

JHPCY vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PS Ratio falls into.


JHPCY
71GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jiangsu Hengrui Pharmaceuticals Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.352/330.2130*330.2130
=0.352

Current CPI (Mar. 2026) = 330.2130.

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.125 241.018 0.171
201609 0.143 241.428 0.196
201612 0.132 241.432 0.181
201703 0.146 243.801 0.198
201706 0.147 244.955 0.198
201709 0.183 246.819 0.245
201712 0.171 246.524 0.229
201803 0.188 249.554 0.249
201806 0.192 251.989 0.252
201809 0.218 252.439 0.285
201812 0.225 251.233 0.296
201903 0.233 254.202 0.303
201906 0.225 256.143 0.290
201909 0.306 256.759 0.394
201912 0.284 256.974 0.365
202003 0.247 258.115 0.316
202006 0.252 257.797 0.323
202009 0.373 260.280 0.473
202012 0.391 260.474 0.496
202103 0.327 264.877 0.408
202106 0.320 271.696 0.389
202109 0.333 274.310 0.401
202112 0.280 278.802 0.332
202203 0.265 287.504 0.304
202206 0.224 296.311 0.250
202209 0.263 296.808 0.293
202212 0.233 296.797 0.259
202303 0.244 301.836 0.267
202306 0.252 305.109 0.273
202309 0.262 307.789 0.281
202312 0.256 306.746 0.276
202403 0.256 312.332 0.271
202406 0.339 314.175 0.356
202409 0.297 315.301 0.311
202412 0.337 315.605 0.353
202503 0.318 319.799 0.328
202506 0.368 322.561 0.377
202509 0.313 324.800 0.318
202512 0.355 324.054 0.362
202603 0.352 330.213 0.352

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Jiangsu Hengrui Pharmaceuticals Co (JHPCY) has a Cyclically Adjusted Revenue per Share of $0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors.
Is Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted Revenue per Share too high?
Jiangsu Hengrui Pharmaceuticals Co's current Cyclically Adjusted Revenue per Share is $0.00. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. Jiangsu Hengrui Pharmaceuticals Co's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (JHPCY) is currently considered Modestly Undervalued. The stock's GF Value™ is $15.12, compared to a current price of $13.60 — trading 10.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.00. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (JHPCY), the current Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (JHPCY) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of $13.60 is trading 10.1% below its estimated GF Value™ of $15.12. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for JHPCY:

  • Cyclically Adjusted Revenue per Share: $0.00
  • GF Value™: $15.12 vs. price of $13.60 (10.1% below fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the JHPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
71GF Score

Get the complete analysis for JHPCY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.60
Price
$15.12
GF Value